Concordia Healthcare Corp. (NASDAQ:CXRX)’s share price traded down 3.6% during mid-day trading on Friday . The company traded as low as $9.18 and last traded at $9.20, with a volume of 330,778 shares. The stock had previously closed at $9.54.

A number of equities analysts have issued reports on the company. TD Securities reiterated a “hold” rating and issued a $14.00 price objective (down previously from $20.00) on shares of Concordia Healthcare Corp. in a report on Wednesday. Zacks Investment Research downgraded Concordia Healthcare Corp. from a “hold” rating to a “strong sell” rating in a report on Wednesday. Canaccord Genuity set a $20.00 price objective on Concordia Healthcare Corp. and gave the stock a “buy” rating in a report on Monday. RBC Capital Markets reiterated an “outperform” rating and issued a $33.00 price objective on shares of Concordia Healthcare Corp. in a report on Monday. Finally, Goldman Sachs Group Inc. decreased their price objective on Concordia Healthcare Corp. from $26.00 to $13.00 and set a “neutral” rating for the company in a report on Monday. Two research analysts have rated the stock with a sell rating, four have given a hold rating and eight have issued a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus target price of $39.72.

The firm’s market cap is $469.36 million. The company’s 50 day moving average is $17.56 and its 200-day moving average is $24.97.

Concordia Healthcare Corp. (NASDAQ:CXRX) last posted its quarterly earnings data on Friday, August 12th. The company reported $1.38 earnings per share (EPS) for the quarter, meeting the Zacks’ consensus estimate of $1.38. The business had revenue of $231.70 million for the quarter, compared to analysts’ expectations of $229.76 million. The business’s quarterly revenue was up 208.1% on a year-over-year basis. Equities analysts predict that Concordia Healthcare Corp. will post $5.73 EPS for the current fiscal year.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.